FGF21 and metabolic dysfunction-associated steatotic liver disease: Although the role of FGF21 in obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD) in humans and animals has been extensively studied (8–10), the hormone's short circulating half-life (30–120 min) and its tendency to aggregate in vitro limit its clinical application (11).